바카라 게임 사이트

The Phase 3 FLAURA2 trial demonstrated that combining Tagrisso (osimertinib) with platinum-based chemotherapy significantly improved progression-free survival (PFS) compared to Tagrisso monotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) as a first-line treatment. The trial included patients with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations in locally advanced or metastatic non-squamous NSCLC. Findings from the sub-analysis involving 169 바카라 게임 사이트 patients in the combination group and 164 in the monotherapy group were presented on December 7 at the ESMO Asia 2024 Annual Meeting.

Professor James Chih-Hsin Yang from National Taiwan University Hospital shared the investigator-assessed median PFS results: 25.5 months (95% CI: 22.3–NC) for the combination therapy group, 6.1 months longer than the 19.4 months observed with monotherapy (HR 0.69, 95% CI: 0.51–0.94). Independent blinded central review (BICR) results further supported these findings, with the combination group showing a median PFS of 33.2 months (95% CI: 25.1–NC) compared to 19.9 months (95% CI: 19.2–NC) for monotherapy (HR 0.72, 95% CI: 0.52–1.01).

These results are consistent with the overall population analysis (ITT) presented at WCLC 2023, where combination therapy extended median PFS by 8.8 months and reduced the risk of disease progression or death by 38% (HR 0.62, 95% CI: 0.49–0.79, p<0.0001).

Median overall survival (OS) results for the combination group were 40.5 months (95% CI: 37.7–NC), compared to 38.3 months (95% CI: 34.3–NC) for monotherapy. However, the data are not yet mature, and statistical significance has not been achieved (HR 0.80, 95% CI: 0.57–1.12).

The 바카라 게임 사이트 cohort’s investigator-assessed objective response rate (ORR) was 84.0%, aligning with the global cohort (83.0%). Median duration of response (DoR) was also consistent at 24.0% (바카라 게임 사이트 cohort 95% CI: 20.7–NC; global cohort 95% CI: 20.9–27.8).

Adverse events of Grade 3 or higher were reported in 58% of the 바카라 게임 사이트 combination group, slightly higher than the global cohort (53%). The most common adverse events in the 바카라 게임 사이트 group were anemia (50%), diarrhea (38%), and nausea (37%).

Professor James Chih-Hsin Yang emphasized, “This sub-analysis confirmed a clinically meaningful PFS benefit and indicated a trend toward OS improvement as data continues to mature. These findings support the use of Tagrisso combined with chemotherapy as an additional first-line treatment option for 바카라 게임 사이트 patients with EGFR-mutated advanced NSCLC, beyond the existing monotherapy.”

AstraZeneca Korea obtained regulatory approval on April 15 for the combination of Tagrisso with platinum-based chemotherapy, making it the first EGFR tyrosine kinase inhibitor (TKI) in South Korea available for both monotherapy and combination therapy as a first-line treatment for EGFR-mutated non-squamous NSCLC.